Silence TherapeuticsSLN +9.01%44 Gross Margin % is 97.39% as of Mar. 2026, which is 96% above its 10-year median of 49.64. GuruFocus rates SLN with a GF Score™ of 44/100 and a GF Value™ of $0.21 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 738 Biotechnology companies, Silence Therapeutics ranks better than 71.82% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Silence Therapeutics had a gross margin of 97.39% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Silence Therapeutics Gross Margin % Related Terms
Silence Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Silence Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLN vs CRBP, TTRX, AGEN: Gross Margin % Comparison
For the Biotechnology subindustry, Silence Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silence Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Silence Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Silence Therapeutics (SLN) has a Gross Margin % of 97.39% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Silence Therapeutics and its competitors. This is 96% above median its historical median of 49.64. Over the past decade, Silence Therapeutics' Gross Margin % has ranged from 31.34 to 79.50. According to the industry distribution chart, Silence Therapeutics ranks #208 out of 738 companies in the Biotechnology industry, placing it in the top 28.2%.
Is Silence Therapeutics' Gross Margin % too high?
Silence Therapeutics' current Gross Margin % of 97.39% is 96% above median its 10-year median of 49.64. Over the past 10 years, this metric has ranged from a low of 31.34 to a high of 79.50. The Biotechnology industry median Gross Margin % is 60.94. Silence Therapeutics' value of 97.39% is 59.8% above this industry median. Based on the distribution chart, Silence Therapeutics ranks #208 out of 738 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Silence Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Gross Margin % compare to CRBP and TTRX?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #208 out of 738 companies for Gross Margin %. This puts Silence Therapeutics in the upper half of its industry. The industry median Gross Margin % is 60.94. Silence Therapeutics' value of 97.39% is 59.8% above this benchmark. Historically, Silence Therapeutics' own Gross Margin % has ranged from 31.34 to 79.50 over the past decade. While the company's 10-year median is 49.64 vs. the industry median of 60.94, Silence Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Silence Therapeutics's current Gross Margin % of 97.39% is 59.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Silence Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Silence Therapeutics's current Gross Margin % is 97.39%, which is 96% above median its own 10-year median of 49.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $9.99 — trading 4654.8% above its estimated fair value. The current Gross Margin % is 97.39%, which is 96% above median its 10-year median of 49.64 and 59.8% above the Biotechnology industry median of 60.94. Silence Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Gross Margin % is 97.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Silence Therapeutics (SLN) Overvalued in 2026?
Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued.
The current stock price of $9.99 is trading 4654.8% above its estimated GF Value™ of $0.21.
GuruFocus considers Silence Therapeutics to be Significantly Overvalued.
Key valuation signals for SLN:
Gross Margin %: 97.39% (96% above median its 10-year median of 49.64)
GF Value™: $0.21 vs. price of $9.99 (4654.8% above fair value)
Industry Position: 59.8% above the Biotechnology median (#208 of 738)
No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
44GF Score
Get the complete analysis for SLN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLN has been successfully added to your 
